In vitro experiments demonstrated that cancer-associated adipocytes upregulate the hexosamine biosynthetic pathway (HBP), leading to O-GlcNAcylation and stabilization of the YAP protein
L-Glutathione Reduced, Reduced Glutathione supplement can improve L-Glutathione Reduced, Reduced Glutathione level in following conditions: adiposity, NIDD, capillary diseases, nephropathy, Parkinson disease, pulmonary disease, AIDS and other diseases, smoke, over consumption of alcohol, large amount of prescription medicine and OTC, radiotherapy and chemotherapy, etc
Week 5-8: Low therapeutic dose (5mg) Weekly dose : 5mg (double from 2.5mg) Why this dose : First therapeutic dose Noticeable appetite suppression Steady weight loss begins Side effects still manageable What to expect : Moderate appetite suppression (40-50%) Consistent 1-2 lb weekly loss Nausea reduces (if present initially) Energy normalizes Total weight loss so far : 6-10 lbs Week 9-12: Medium dose (7.5mg) Weekly dose : 7.5mg Why this dose : Increased effectiveness Strong appetite control Accelerated fat loss Still tolerable for most What to expect : Strong appetite suppression (60-70%) 1.5-2 lbs weekly loss Minimal side effects (body adapted) Improved insulin sensitivity Total weight loss so far : 12-18 lbs Week 13-16: High therapeutic dose (10mg) Weekly dose : 10mg Why this dose : Maintenance dose for many users Maximum appetite suppression Optimal metabolic effects Sustainable long-term What to expect : Very strong appetite control (70-80%) Continued 1-2 lb weekly loss Minimal hunger most days Excellent insulin control Total weight loss so far : 18-26 lbs Week 17-20: Maximum dose (12.5-15mg) Weekly dose : 12.5mg or 15mg (optional) Why this dose : For those who plateau at 10mg Additional 3-5% weight loss Maximum therapeutic effect Not needed by everyone What to expect : Maximum suppression (80-90%) Final 5-10 lbs to goal Very little hunger Excellent metabolic health Total weight loss (20 weeks) : 25-35 lbs average Note : Many people maintain at 10mg
Innate immunity and neurodegeneration
BPC-157 does not cause traditional tolerance or require post-cycle therapy like hormonal compounds
